Urology Today.net

Site updated at Thursday, 12 May 2016

Common Urological Problems


FDA Approves Xtandi for Late-Stage Castration-Resistant Prostate Cancer

The U.S. Food and Drug Administration today approved Xtandi (enzalutamide) to treat men with late-stage (metastatic) castration-resistant prostate cancer that has spread or recurred, even with medical or surgical therapy to minimize testosterone.

Approved for prostate cancer patients previously treated with docetaxel, another anti-cancer treatment, Xtandi was reviewed under the FDA’s priority review program.… FDA Approves Xtandi for Late-Stage Castration-Resistant Prostate Cancer   

urinary tract defects1 - intravenous fluids1 - neurological disorder1 - bladder pressure4 - intrauterine devices1 - pelvic ureter1 - jama1 - kidneys filter1 - critical care1 - male pattern baldness1 - sex therapy1 - hyperuricemia1 - psa testing3 - coccyx1 - radiotherapy3 - asn14 - phytotherapy1 - developmental biology1 - nephrolithiasis2 - antibiotic treatment1 - infundibula1 - streptococcal infection1 - retinopathy1 - boston university school of medicine1 - proteins rala1 - distal tubule1 - collagen diseases1 - low risk tumors1 - urine tests1 - advanced renal disease1 -